pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
407
stories
13h
Cancer vaccine win restores Wall Street’s faith in Moderna
biopharma dive
14h
Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trial
endpoints
18h
STAT+: One of the most consequential years for cancer treatment, ever
stat
1d
Why pediatric rare oncology outperforms in a volatile biotech market
biospace
1d
B. Braun Medical Inc. Issues Voluntary North American Recall of Excel® Lactated Ringers Injection, 1000mL Due to the Presence of Particulate Matter
fda recalls
1d
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy
fiercebiotech
1d
Optimal Balance Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin Levels
fda recalls
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
biopharma dive
1d
Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein
fiercebiotech
1d
She grew up unvaccinated. Now she’s a leading voice for science — and empathy
stat
2d
Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
fiercebiotech
2d
Exclusive: Third death revealed in China's popular but opaque trials
endpoints
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
3d
Argenx jumps on Phase 3 data for blockbuster Vyvgart
biopharma dive
3d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
3d
Biotech's reverse merger renaissance poised to continue
endpoints
3d
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
3d
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
3d
Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
endpoints
3d
Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
fiercebiotech
4d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
6d
The Hampton Grocers, Inc . Recalls It’s 8 Ounce Packages of “Lacnola Lactation Granola” Because of Possible Health Risk
fda recalls
6d
Opinion: AAP president: How pediatricians are navigating federal leaders’ fearmongering on vaccines
stat
6d
STAT+: PBMs agree to display TrumpRx drug prices
stat
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
6d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
6d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
← prev
page 1 of 14
next →
